ABSTRACT SUBMISSION GUIDELINES 

• Abstracts must be submitted electronically using the official online submission form 

• Abstracts must identify the presenting author along with email address  

• Please use standard abbreviations. Place special or unusual abbreviations in parenthesis after the full word when it appears for the first time 

• Errors, misspellings, and incorrect abbreviations will not be corrected 

• Abstracts will be presented in capital letter case 

• An individual may submit more than one (1) abstract. One official online submission is required for each abstract 

• Edits to submitted abstracts may be made up to the submission deadline. Instructions for making edits can be found on the submission site 

• Abstracts must be submitted by October 9, 2024 to be considered for presentation. 

ABSTRACT TYPES   

During the online abstract submission, authors will be requested to select their preferred method of presentation: Oral or Poster Presentation or Poster only Presentation. 

Presentation method preferences will be considered during the review process.

SESSION THEMES (TOPICS)   

Themes (topics) for each of the sessions are listed below. Please submit your abstract within the Basic Science, Clinical or Public Health streams under one of the following subtopics: 

Basic-translational science categories 

1. HCV/flavivirus virology
2. HCV/flavivirus immunology
3. HBV/HDV virology 
4. HBV/HDV immunology
5. Preclinical therapeutics HBV/HDV
6. Hepatocellular carcinoma
7. Other viruses (including HEV)
8. Liver inflammation and fibrogenesis 
9. Liver pathogen detection and discovery 

Clinical science categories 

10. HCV screening, clinical care delivery and outcomes
11. HBV screening, clinical care delivery and outcomes
12. Approved HBV treatments
13. New and promising HBV therapies (Phase 2 and beyond) and diagnostics
14. Approved and promising new HDV therapies and diagnostics
15. Viral hepatitis coinfections and morbidities:  HIV, MASLD/MASH
16. Hepatocellular carcinoma clinical
17. Hepatocellular carcinoma treatment
18. Biomarkers for liver diseases
19. Other viruses, clinical and treatment

Public Health categories 

20. Prevention of new infections, including vaccination and injection safety
21. Epidemiology of HCV
22. Epidemiology of HBV/HDV
23. Epidemiology of hepatocellular carcinoma
24. HBV elimination: achievements and challenges
25. HCV elimination: achievements and challenges
26. Simplified community and clinic- based approaches to viral hepatitis care cascade
27. Strategies for equitable service delivery to overcome disparities in viral hepatitis

The abstract review committee reserves the right to reassign submitted abstracts to a different session. 

ABSTRACT FORMATTING GUIDELINES  

Please adhere to the following formatting guidelines when submitting your abstracts for GHS 2025. Abstracts that are not correctly formatted will not be reviewed. 

• The abstract title should not exceed 300 characters 

• The abstracts should not exceed 3,000 characters 

• Each abstract is allowed to include a maximum of three (3) caption (figure or table) but this is not a requirement. Minimize the use of charts and graphics as this detail is not used to evaluate the merit of your abstract 

• There is no restriction on your abstract structure, but we recommended the following: 

• • Title 

• • Background 

• • Purpose 

• • Method(s) 

• • Result(s) 

• • Conclusion(s) 

NOTIFICATION OF ACCEPTANCE    

Presenting authors will be notified of their acceptance status in early November 2024. Presenting authors must inform any co-author(s) of acceptance. The organizing committee reserves the right to accept or decline any submissions and to select the presentation format (oral or poster). 

DISCLOSURE OF CONFLICTS OF INTEREST 

The presenting authors of abstracts selected for oral presentation will be required to complete and submit a Disclosure of Conflicts of Interest form after they are invited to present. Disclosures are due on or before the RSVP deadline. 

DISCLAIMER REGARDING THE SUBMISSION OF ABSTRACTS 

The Conference Organizers will not be held responsible for abstract submissions not received via the website or for submission errors caused by internet service outages, hardware or software delays, power outages or unforeseen events. 

For any questions or assistance regarding abstract submissions, please contact:  [email protected]